|Bid||24.72 x 800|
|Ask||24.83 x 800|
|Day's range||24.22 - 24.87|
|52-week range||17.19 - 30.14|
|Beta (5Y monthly)||0.53|
|PE ratio (TTM)||23.58|
|Earnings date||13 Feb 2023 - 17 Feb 2023|
|Forward dividend & yield||N/A (N/A)|
|1y target est||34.20|
In this article we are going to estimate the intrinsic value of Corcept Therapeutics Incorporated ( NASDAQ:CORT ) by...
Corcept's (CORT) Cushing's syndrome drug Korlym is witnessing higher sales and a strong uptake since approval. However, sole dependence on Korlym for revenues remains a headwind.
Durect (DRRX) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.